Tumour necrosis factor α inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients
Identifieur interne : 001F36 ( Main/Exploration ); précédent : 001F35; suivant : 001F37Tumour necrosis factor α inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients
Auteurs : C. Pritchard [États-Unis] ; K. Nadarajah [États-Unis]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2004-03.
English descriptors
- KwdEn :
- Teeft :
- Active disease, Adhesion molecules, Approximate duration, Arthralgia, Assistive devices, Case reports, Caucasian woman, Conventional treatments, Cyclosporin, Cytokine, Daily methotrexate, Differential efficacy, Dosing interval, Gait dysfunction, Glucocorticoid, Glucocorticoids hydroxychloroquine, Granuloma, Human alveolar macrophages, Human mouse antibody, Hydroxychloroquine, Inflammatory, Infliximab, Infliximab treatment, Infusion, Inhibitor, Inhibitor treatment, Macrophage, Magnetic resonance imaging, Maximum dosage, Methotrexate, Months cyclosporin, Nadarajah, Necrosis, Neurosarcoidosis, Other immunomodulatory treatments, Other patients, Pulmonary disease, Pulmonary sarcoidosis, Refractory sarcoidosis, Respir crit care, Rheumatoid, Rheumatoid arthritis, Sarcoid, Sarcoid endometritis, Sarcoid uveitis, Sarcoidosis, Sarcoidosis vasc, Skin nodules, Thoracic spine, Tnfa, Tnfa inhibitor treatment, Tnfa inhibitors, Tumour, Tumour necrosis factor, Uveitis.
Abstract
Objective: To study the effectiveness of tumour necrosis factor α (TNFα) inhibitor treatment for sarcoidosis refractory to conventional treatments. Methods: Five patients (two men, three women) were treated with infliximab. All patients received a loading dose of 3 mg/kg at 0, 2, and 6 weeks and then maintenance infusions every 4–8 weeks. Patients had their dose increased or the dosing interval reduced when the disease relapsed. These patients had active disease despite treatment with corticosteroids and other immunomodulatory agents. All patients had a negative tuberculin skin test. Results: Sarcoidosis in all patients improved significantly without any serious adverse reactions. Conclusion: This study suggests that TNFα is effective in patients for whom conventional treatment fails.
Url:
DOI: 10.1136/ard.2002.004226
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001048
- to stream Istex, to step Curation: 001048
- to stream Istex, to step Checkpoint: 000D77
- to stream Main, to step Merge: 001F51
- to stream Main, to step Curation: 001F36
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tumour necrosis factor α inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients</title><author><name sortKey="Pritchard, C" sort="Pritchard, C" uniqKey="Pritchard C" first="C" last="Pritchard">C. Pritchard</name></author><author><name sortKey="Nadarajah, K" sort="Nadarajah, K" uniqKey="Nadarajah K" first="K" last="Nadarajah">K. Nadarajah</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:415F619A6A8D8CC137BB0B76AB07F5916DEAC221</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1136/ard.2002.004226</idno><idno type="url">https://api.istex.fr/ark:/67375/NVC-4GPP84TL-4/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001048</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001048</idno><idno type="wicri:Area/Istex/Curation">001048</idno><idno type="wicri:Area/Istex/Checkpoint">000D77</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000D77</idno><idno type="wicri:doubleKey">0003-4967:2004:Pritchard C:tumour:necrosis:factor</idno><idno type="wicri:Area/Main/Merge">001F51</idno><idno type="wicri:Area/Main/Curation">001F36</idno><idno type="wicri:Area/Main/Exploration">001F36</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Tumour necrosis factor α inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients</title><author><name sortKey="Pritchard, C" sort="Pritchard, C" uniqKey="Pritchard C" first="C" last="Pritchard">C. Pritchard</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Rheumatology Specialty Center, 2400 Maryland Road, Suite 40, Willow Grove, PA 19090</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Nadarajah, K" sort="Nadarajah, K" uniqKey="Nadarajah K" first="K" last="Nadarajah">K. Nadarajah</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Rheumatology Specialty Center, 2400 Maryland Road, Suite 40, Willow Grove, PA 19090</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2004-03">2004-03</date><biblScope unit="volume">63</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="318">318</biblScope></imprint><idno type="ISSN">0003-4967</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>ACE, angiotensin converting enzyme</term><term>CT, computed tomography</term><term>IL, interleukin</term><term>MRI, magnetic resonance imaging</term><term>TNFα, tumour necrosis factor α</term><term>infliximab</term><term>sarcoidosis</term><term>tumour necrosis factor α</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Active disease</term><term>Adhesion molecules</term><term>Approximate duration</term><term>Arthralgia</term><term>Assistive devices</term><term>Case reports</term><term>Caucasian woman</term><term>Conventional treatments</term><term>Cyclosporin</term><term>Cytokine</term><term>Daily methotrexate</term><term>Differential efficacy</term><term>Dosing interval</term><term>Gait dysfunction</term><term>Glucocorticoid</term><term>Glucocorticoids hydroxychloroquine</term><term>Granuloma</term><term>Human alveolar macrophages</term><term>Human mouse antibody</term><term>Hydroxychloroquine</term><term>Inflammatory</term><term>Infliximab</term><term>Infliximab treatment</term><term>Infusion</term><term>Inhibitor</term><term>Inhibitor treatment</term><term>Macrophage</term><term>Magnetic resonance imaging</term><term>Maximum dosage</term><term>Methotrexate</term><term>Months cyclosporin</term><term>Nadarajah</term><term>Necrosis</term><term>Neurosarcoidosis</term><term>Other immunomodulatory treatments</term><term>Other patients</term><term>Pulmonary disease</term><term>Pulmonary sarcoidosis</term><term>Refractory sarcoidosis</term><term>Respir crit care</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Sarcoid</term><term>Sarcoid endometritis</term><term>Sarcoid uveitis</term><term>Sarcoidosis</term><term>Sarcoidosis vasc</term><term>Skin nodules</term><term>Thoracic spine</term><term>Tnfa</term><term>Tnfa inhibitor treatment</term><term>Tnfa inhibitors</term><term>Tumour</term><term>Tumour necrosis factor</term><term>Uveitis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: To study the effectiveness of tumour necrosis factor α (TNFα) inhibitor treatment for sarcoidosis refractory to conventional treatments. Methods: Five patients (two men, three women) were treated with infliximab. All patients received a loading dose of 3 mg/kg at 0, 2, and 6 weeks and then maintenance infusions every 4–8 weeks. Patients had their dose increased or the dosing interval reduced when the disease relapsed. These patients had active disease despite treatment with corticosteroids and other immunomodulatory agents. All patients had a negative tuberculin skin test. Results: Sarcoidosis in all patients improved significantly without any serious adverse reactions. Conclusion: This study suggests that TNFα is effective in patients for whom conventional treatment fails.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Pennsylvanie</li></region></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Pritchard, C" sort="Pritchard, C" uniqKey="Pritchard C" first="C" last="Pritchard">C. Pritchard</name></region><name sortKey="Nadarajah, K" sort="Nadarajah, K" uniqKey="Nadarajah K" first="K" last="Nadarajah">K. Nadarajah</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F36 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F36 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:415F619A6A8D8CC137BB0B76AB07F5916DEAC221
|texte= Tumour necrosis factor α inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients
}}
| This area was generated with Dilib version V0.6.33. |  |